For coronavirus patients, remdesivir may be a solution, according to the European Medicines Agency (EMA). It recommends this Thursday the authorization of a “conditional marketing” of this antiviral within the European Union.
"Remdesivir is the first Covid-19 drug to be recommended for authorization in the EU," the Amsterdam-based agency said in a statement, adding that the recommendation must now be approved or not by the European Commission. It must make its decision over the next week, said the EMA.
Faster recovery in the seriously ill
The agency's recommendation concerns the treatment of the new coronavirus in adults and adolescents from 12 years of age, suffering from pneumonia and needing an oxygen supplement, that is to say those "suffering from a serious illness ".
An EMA study found that patients with Covid-19 treated with remdesivir recovered on average four days faster than other patients.
Originally developed for Ebola haemorrhagic fever, remdesivir from the American laboratory Gilead is the first therapy to have demonstrated some efficacy in patients hospitalized for Covid-19 in a clinical trial of significant size, even if the effect is considered to be modest. . The emergency use of remdesivir in hospitals has been authorized by the United States, then by Japan.
Politics
Coronavirus: Before the commission of inquiry, Didier Raoult strangles the scientific council and the French screening strategy
Science
Coronavirus: What you need to know about the two contradictory studies on the efficacy of remdesivir
- Health
- Drug
- Covid 19
- EU
- Coronavirus